Thursday, April 08, 2021 9:50:53 AM
You misunderstand or don’t read very well.
I did not say that NWBO is partnering with any pharma in Edmonton or Canada for that matter.
I simply wondered why a relatively low level Deloitte employee living in Edmonton of all remote places was hired by NWBO. Just because her father was involved with DC VAX does not qualify her for employment or make her a great advocate. Hiring a CFA in Edmonton with no pharma or regulatory/ gov’t experience or contacts certainly raises questions at least for me. What is the attraction in Edmonton? I tried to find some and I related what I found. Not really very attractive as the pharma companies are rather small. Funds? You can find them in better placed cities in Canada vis-a-vis Edmonton.
So, I for one am rather befuddled by this particular hire. What will she be doing all day long?
I did not say that NWBO is partnering with any pharma in Edmonton or Canada for that matter.
I simply wondered why a relatively low level Deloitte employee living in Edmonton of all remote places was hired by NWBO. Just because her father was involved with DC VAX does not qualify her for employment or make her a great advocate. Hiring a CFA in Edmonton with no pharma or regulatory/ gov’t experience or contacts certainly raises questions at least for me. What is the attraction in Edmonton? I tried to find some and I related what I found. Not really very attractive as the pharma companies are rather small. Funds? You can find them in better placed cities in Canada vis-a-vis Edmonton.
So, I for one am rather befuddled by this particular hire. What will she be doing all day long?
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
